Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

Read narrative

Sanofi Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sanofi
Historical stock prices
Current Share Price	€73.10
52 Week High	€94.10
52 Week Low	€73.30
Beta	0.28
1 Month Change	-9.61%
3 Month Change	-9.03%
1 Year Change	-21.33%
3 Year Change	-26.38%
5 Year Change	-15.71%
Change since IPO	75.72%

Recent updates

Analysis Article • May 04

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...

Narrative Update • Apr 22

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.

New Narrative • Apr 14

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

Narrative Update • Apr 07

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.

New Narrative • Mar 31

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

Narrative Update • Mar 24

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.

Narrative Update • Mar 09

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.

Narrative Update • Feb 23

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.

Narrative Update • Feb 09

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.

Narrative Update • Jan 25

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.

Narrative Update • Jan 11

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.

Narrative Update • Dec 25

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.

Narrative Update • Dec 11

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.

Narrative Update • Nov 27

SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals

Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.

Narrative Update • Nov 10

SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution

Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.

Analysis Article • Oct 31

We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative

Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...

Narrative Update • Oct 27

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.

Narrative Update • Sep 12

Pipeline Advances And Acquisitions Will Expand Therapeutic Horizons

Sanofi's slight decline in future P/E alongside an improved net profit margin suggests a modestly stronger earnings outlook, although this was not enough to materially shift the consensus analyst price target, which decreased fractionally from €109.22 to €108.31. What's in the News FDA approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) after insufficient response to previous treatment, based on positive Phase 3 results; also approved in UAE and under review in EU and China, with Fast Track and Orphan Drug designations for multiple indications.

Analysis Article • Jul 27

Cautious Investors Not Rewarding Sanofi's (EPA:SAN) Performance Completely

With a median price-to-earnings (or "P/E") ratio of close to 16x in France, you could be forgiven for feeling...

Shareholder Returns

	SAN	FR Pharmaceuticals	FR Market
7D	-8.4%	-7.2%	0.5%
1Y	-21.3%	-14.5%	0.7%

Return vs Industry: SAN underperformed the French Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: SAN underperformed the French Market which returned 0.7% over the past year.

Price Volatility

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	4.1%
Market Average Movement	5.4%
10% most volatile stocks in FR Market	10.6%
10% least volatile stocks in FR Market	2.9%

Stable Share Price: SAN has not had significant price volatility in the past 3 months compared to the French market.

Volatility Over Time: SAN's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	74,846	Belen Garijo Lopez	www.sanofi.com

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.

Sanofi Fundamentals Summary

How do Sanofi's earnings and revenue compare to its market cap?
SAN fundamental statistics
Market cap	€88.50b
Earnings (TTM)	€4.83b
Revenue (TTM)	€47.35b

18.2x

P/E Ratio

1.9x

P/S Ratio

Is SAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SAN income statement (TTM)
Revenue	€47.35b
Cost of Revenue	€13.09b
Gross Profit	€34.26b
Other Expenses	€29.44b
Earnings	€4.83b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	4.02
Gross Margin	72.36%
Net Profit Margin	10.20%
Debt/Equity Ratio	24.9%

How did SAN perform over the long term?

See historical performance and comparison

Dividends

5.6%

Current Dividend Yield

102%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/08 12:40
End of Day Share Price	2026/05/08 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sanofi is covered by 53 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi (SAN) Stock Overview

Rewards

Risk Analysis

Analyst Price Targets

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Top Analyst Narratives

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Looking to be second time lucky with a game-changing new product

Sanofi Competitors

Ipsen

Virbac

Vetoquinol

Boiron

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Expands Vaccine Portfolio With Dynavax Acquisition and Invests in AI Growth in Toronto

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi Announces Board and Committee Changes

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of €4.12 per share

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Expands Vaccine Portfolio With Dynavax Acquisition and Invests in AI Growth in Toronto

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi Announces Board and Committee Changes

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of €4.12 per share

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Dividend increased to €4.12

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

New minor risk - Dividend sustainability

Full year 2025 earnings: EPS misses analyst expectations

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes